7-(4-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)butoxy)-4-phenylchroman-2-one | 1338325-75-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 新黄酮类化合物
• 英文名称: 7-(4-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)butoxy)-4-phenylchroman-2-one
• 英文别名: 7-[4-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butoxy]-4-phenyl-3,4-dihydrochromen-2-one；7-[4-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]butoxy]-4-phenyl-3,4-dihydrochromen-2-one
• CAS: 1338325-75-9
• 化学式: C₃₁H₃₁FN₂O₄
• 分子量: 514.597
• InChiKey: AKQZHGSOGBAINA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  38
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  64.8
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  (±)-7-hydroxy-4-phenyl-3,4-dihydrocoumarin 在 potassium carbonate 、 potassium iodide 作用下， 以 丙酮 、 乙腈 为溶剂， 反应 18.0h， 生成 7-(4-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)butoxy)-4-phenylchroman-2-one
  参考文献：
  名称：

  BENZOPYRONE DERIVATIVE AND USE THEREOF

  摘要：

  本发明涉及制药化学领域，具体地说，涉及一种苯并吡喃衍生物及其用途。该苯并吡喃衍生物是具有结构式(I)或其药用可接受盐的化合物。经实验证明，这类化合物在预防或治疗神经精神疾病方面具有用途。

  公开号：

  US20140113911A1

文献信息

• [EN] BENZOPYRONE DERIVATIVE AND USE THEREOF<br/>[FR] DÉRIVÉ DE LA BENZOPYRONE ET SON UTILISATION
  申请人：UNIV HUAZHONG SCIENCE TECH

  公开号：WO2012136147A1

  公开（公告）日：2012-10-11

  本发明属于药物化学领域，具体涉及一种苯并吡喃酮类衍生物及其应用。所述苯并吡喃酮类衍生物为具有式（I）结构的化合物或其药学上可接受的盐。经实验发现，该类化合物可用于预防或治疗神经精神类疾病。
• Synthesis and Biological Investigation of Coumarin Piperazine (Piperidine) Derivatives as Potential Multireceptor Atypical Antipsychotics
  作者：Yin Chen、Songlin Wang、Xiangqing Xu、Xin Liu、Minquan Yu、Song Zhao、Shicheng Liu、Yinli Qiu、Tan Zhang、Bi-Feng Liu、Guisen Zhang

  DOI：10.1021/jm400408r

  日期：2013.6.13

  The discovery and synthesis of potential and novel antipsychotic coumarin derivatives, associated with potent dopamine 132, D3, and serotonin S-HT1A and S-HT2A, receptor properties, are the focus of the present article. The most-promising derivative was 7-(4-(4-(6-fluorobenzo[d]-isoxazol-3-yl)-piperidin-1-yl)butoxy)-4-methyl-8-chloro-2H- chromen-2-one (17m). This derivative possesses unique pharmacological features, including high affinity for dopamine D-2 and D-3 and serotonin S-HT1A and 5-HT2A receptors. Moreover, it possesses low affinity for S-HT2C and H-1 receptors (to reduce the risk of obesity associated with chronic treatment) and hERG channels (to reduce the incidence of torsade des pointes). In animal models, compound 17m inhibited apomorphine-induced climbing behavior, MK-801-induced hyperactivity, and the conditioned avoidance response without observable catalepsy at the highest dose tested. Further, fewer preclinical adverse events were noted with 17m compared with risperidone in assays that measured prolactin secretion and weight gain. Acceptable pharmacokinetic properties were also noted with 17m. Taken together, 17m may constitute a novel class of drugs for the treatment of schizophrenia.
• US9315496B2
  申请人：——

  公开号：US9315496B2

  公开（公告）日：2016-04-19